Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Abbott’s new 45 mg six-month formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced prostate cancer.
Subscribe to our email newsletter
Lupron Depot, which belongs to a class of medications known as gonadotropin releasing hormone (GnRH) agonists, suppresses the production of the hormone testosterone.
This testosterone suppression can help slow or stop the growth of hormone-dependent cancer cells, and may reduce pain and other symptoms related to advanced prostate cancer.
The FDA’s approval was backed by new data from a 48-week, open-label study, in which 151 prostate cancer patients who received a total of two injections, 24 weeks apart, were followed for nearly 12 months to evaluate testosterone suppression and safety.
Overall, testosterone suppression with this new 45 mg six-month depot formulation was sustained in patients throughout the treatment period.